Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Recruiting

Phase 3

Cevostamab & Pomalidomide & DexamethasoneCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Sponsor:

Hoffmann-La Roche

Code:

NCT07555938

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cevostamab

Pomalidomide

Dexamethasone

Daratumumab

Elotuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-13. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-07-20.